CDKN2B-AS1 and central nervous system cancer: Sun et al. [97] found that levels of LncRNA-ANRIL and SOX9 in the serum of glioma patients were significantly higher than in healthy individuals, and high expression of LncRNA-ANRIL and SOX9 was closely associated with poor prognosis, providing important value for diagnosing different grades of glioma.